Panda Perspectives
Mari Savickis, VP of Public Policy for CHIME, joins Panda Perspectives live from the VIVE show floor to break down how shifting federal priorities and political uncertainty are impacting digital health progress. As a longtime healthcare policy expert, Mari offers a behind-the-scenes look at how providers are reacting to rapid changes in Washington, highlighting how…
Latest
Healthcare
Charlotte Piper with Ochsner Health
Charlotte Piper, Assistant Vice President of Ochsner Ventures, joins Panda Perspectives to explore how Ochsner Health is leveraging innovation, strategic investment, and deep collaboration to drive real change in healthcare. With a mission to create new value—financial and operational—for the health system, Charlotte shares how her team works across partnerships, internal ventures, and digital transformation…
Healthcare
Sam Shields with Dartmouth Health
Sam Shields, System VP of Strategy and Regional Operations at Dartmouth Health, joins Panda Perspectives to discuss how the academic health system is navigating digital transformation in a rural setting. With a recently completed strategic plan, Dartmouth is focused on enhancing care for its aging population through innovative models, AI governance, and robust telehealth infrastructure….
Healthcare
David Clayton
In this Panda Perspectives episode, Duke Health’s David Claxton shares insights on measuring digital health ROI, drawing from his experience in both health systems and as a former digital health vendor. He discusses challenges in validating ROI claims, the importance of realistic vendor partnerships, and the surprising under-prioritization of clinic time savings. David highlights Duke’s…
Healthcare
Digital Health ROI Report
In this episode of Panda Perspectives, Panda Health’s Amy Oliver and David Jastrow dive into their newly released digital health ROI report, discussing surprising findings and key takeaways. They explore how hospital leaders prioritize patient outcomes, experience, and quality over cost savings, while also addressing skepticism around vendors’ ROI claims.
Healthcare
This Week Health Discussion
In this episode of Panda Perspectives, Jason Taylor sits down with Sarah and Drex from This Week Health to reflect on the key takeaways from the recent 229 city tour dinners. They explore the unique challenges healthcare leaders are facing, the importance of fostering connections in local communities, and the powerful role vulnerability plays in…
Latest
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…
What’s Next in Preclinical Cancer Immunotherapy Research?
As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…
Analyzing the Suppressive TME in In Vitro Based Assays
In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…
